ALT

Business Context and Reporting Period

This Form 10-Q covers the quarterly period ended September 30, 2007, for PharmAthene, Inc. (formerly Healthcare Acquisition Corporation). The filing reflects a significant corporate restructuring: on August 3, 2007, the company completed a reverse merger with Healthcare Acquisition Corporation (HAQ). PharmAthene is a biopharmaceutical company focused on developing anti-infectives for biodefense applications, specifically Valortim (anthrax treatment) and Protexia (nerve agent prophylaxis).

Key Financial Metrics

Note: The company reported a net loss of $(0.32) million for the quarter, which was significantly offset by non-cash items including a $1.21 million gain on debt extinguishment and a $2.43 million gain from the change in market value of derivative instruments. Excluding these items, the operating loss was approximately $4.0 million.

Material Changes vs. Prior Period

• Revenue Surge: Revenue increased from $1,590 in the prior year quarter to $3.37 million, driven by a multi-year contract with the U.S. Department of Defense (DoD) for the development of Protexia.
• Liquidity Transformation: Cash and cash equivalents increased from $5.11 million (Dec 31, 2006) to $60.34 million (Sep 30, 2007). This $55.2 million increase was primarily due to $58.7 million in proceeds from the reverse merger with HAQ and a $10 million bank loan.
• Debt Restructuring: The company extinguished $12.8 million in "Bridge Notes" and replaced them with $12.3 million in new unsecured 8% convertible notes. Additionally, a $10 million credit facility was secured in March 2007.
• Operating Expenses: Research and Development (R&D) expenses rose to $3.65 million for the quarter (from $1.67 million YoY) and General and Administrative (G&A) expenses rose to $3.15 million (from $1.61 million YoY), reflecting increased development activities and transaction costs associated with the merger.

Outlook, Risks, and Management Commentary

• Government Contracts: The company secured a $13.9 million contract in September 2007 from NIAID/BARDA for the advanced development of Valortim. The existing DoD contract for Protexia is valued at up to $213 million if all options are exercised.
• Facility Closure: In a subsequent event (November 12, 2007), the company closed its Canadian research facility (VSL) in Montreal, estimating $0.6 million in termination and lease costs. This decision was made as the Protexia program advanced to GMP manufacturing, reducing the need for the transgenic goat research platform.
• Liquidity and Going Concern: While cash reserves are strong post-merger, the company has incurred cumulative net losses and expects to continue doing so. Future capital requirements depend on the success of R&D programs and the ability to secure additional government grants or financing.
• Risks: Key risks include the failure of R&D projects, inability to obtain regulatory approval, and the uncertainty of commercial viability for biodefense products. The company relies heavily on government funding.

Investor Verification Checklist

• Merger Accounting: Verify the treatment of the reverse merger with HAQ and the retroactive restatement of equity.
• Non-Cash Adjustments: Confirm the impact of the $1.2 million debt extinguishment gain and $2.4 million derivative instrument gain on the reported net loss.
• Contractual Obligations: Review the $48.6 million in total contractual obligations, including $25.8 million in notes payable and $4.6 million in operating leases.
• Facility Closure Costs: Monitor the actual costs incurred from the November 2007 closure of the Canadian facility against the estimated $0.6 million.
• Government Funding Reliance: Assess the progress of the DoD and NIAID contracts, as these are the primary revenue drivers.